Due to the federal government shutdown, the eCQI Resource Center has paused updates to site information.
Any updates, questions, and requests will resume when the government is re-opened. Note this includes all eCQM related help desks and Jira.
Top
Official websites use
.gov
A .gov website belongs to an official government organization in the United States.
Secure
.gov
websites use HTTPS
A
lock
(
)
or
https://
means you’ve safely connected to the
.gov
website. Share sensitive information only on official, secure websites.
["Allergy, Intolerance": "Beta Blocker Therapy Ingredient"]
Performance/Reporting Period
2021
Value Set Description from VSAC
Clinical Focus: This value set contains concepts that represent beta blocker therapy ingredients.
Data Element Scope: This value set may use Quality Data Model (QDM) category related to Allergy/Intolerance.
Inclusion Criteria: Includes only relevant concepts associated with prescribable ingredient only.
Exclusion Criteria: No exclusions.
Data Element Scope: This value set may use Quality Data Model (QDM) category related to Allergy/Intolerance.
Inclusion Criteria: Includes only relevant concepts associated with prescribable ingredient only.
Exclusion Criteria: No exclusions.
Constrained to codes in the Allergy, Intolerance: Beta Blocker Therapy Ingredient value set (2.16.840.1.113883.3.526.3.1493)
QDM Datatype and Definition
"Allergy Intolerance"
Data elements that meet criteria using this datatype should document the allergy or intolerance and its corresponding value set.
Timing:
- The prevalence period references the time from the onset date to the abatement date. Often an abatement date is not present as allergy or intolerance is ongoing.
- The author dateTime references the recorded time.
QDM Attributes
prevalencePeriod
Prevalance Period is the time from onset dateTime to abatement dateTime.
Last Updated: Jul 08, 2021